By Patrick Wingrove and Dan Levine
April 25, 2025 – 6:29 AM PDT
Advertisement
(Reuters) – A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk’s (NOVOb.CO) popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records showed.
The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration’s decision that there was no longer a shortage of the medicines’ active ingredient, semaglutide.
Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand.
They had been allowed to produce hundreds of thousands of doses of copies of Novo’s obesity and diabetes drugs only while the FDA said…



